Published in Clin Cancer Res on October 05, 2011
Reuse of public genome-wide gene expression data. Nat Rev Genet (2012) 2.79
Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One (2012) 1.25
Adulthood Weight Change and Risk of Colorectal Cancer in the Nurses' Health Study and Health Professionals Follow-up Study. Cancer Prev Res (Phila) (2015) 1.10
Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget (2015) 1.09
Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer (2014) 1.00
Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer (2014) 0.98
Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Mod Pathol (2013) 0.92
Identification of candidate susceptibility genes for colorectal cancer through eQTL analysis. Carcinogenesis (2014) 0.90
A novel colorectal cancer risk locus at 4q32.2 identified from an international genome-wide association study. Carcinogenesis (2014) 0.89
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer (2014) 0.82
Comprehensive site-specific whole genome profiling of stromal and epithelial colonic gene signatures in human sigmoid colon and rectal tissue. Physiol Genomics (2016) 0.76
Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: A comparison with colon and rectal cancers. Mol Clin Oncol (2013) 0.76
A pilot study comparing protein expression in different segments of the normal colon and rectum and in normal colon versus adenoma in patients with Lynch syndrome. J Cancer Res Clin Oncol (2013) 0.75
Impact of homeobox genes in gastrointestinal cancer. World J Gastroenterol (2016) 0.75
The association between microsatellite instability and lymph node count in colorectal cancer. Virchows Arch (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
ArrayExpress--a public database of microarray experiments and gene expression profiles. Nucleic Acids Res (2006) 8.92
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Are there two sides to colorectal cancer? Int J Cancer (2002) 5.18
Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol (2006) 4.30
Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med (1990) 4.23
Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03
The Hox genes and their roles in oncogenesis. Nat Rev Cancer (2010) 3.97
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res (2009) 3.08
Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut (2005) 2.13
Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst (2001) 1.90
Colorectal cancer, one entity or three. J Zhejiang Univ Sci B (2009) 1.70
Hox transcription factors and their elusive mammalian gene targets. Heredity (Edinb) (2006) 1.70
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. Cancer (2003) 1.62
CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int (2011) 1.62
Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur J Cancer (2005) 1.60
A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology (2009) 1.52
NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer Res (2006) 1.50
DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clin Cancer Res (2008) 1.44
Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res (2006) 1.32
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene (2002) 1.30
The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. J Pathol (2008) 1.25
How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. J Gastrointest Surg (2008) 1.19
Map of differential transcript expression in the normal human large intestine. Physiol Genomics (2007) 1.11
Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer. J Surg Oncol Suppl (1993) 1.05
MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer. Int J Cancer (2010) 1.05
Lifestyle factors, obesity and the risk of colorectal adenomas in EPIC-Heidelberg. Cancer Causes Control (2009) 1.04
The gene expression profile represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol (2007) 1.03
Position-specific expression of Hox genes along the gastrointestinal tract. Congenit Anom (Kyoto) (2004) 1.02
Aberrant expressions of HOX genes in colorectal and hepatocellular carcinomas. Oncol Rep (2010) 1.02
Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J Surg Res (2005) 0.97
Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene (2004) 0.92
CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res (2005) 0.91
Adjuvant therapy for colorectal cancer: present and future perspectives. Dis Colon Rectum (1997) 0.82
Expression of HOX homeobox genes in the adult human colonic mucosa (and colorectal cancer?). Int J Mol Med (2005) 0.81
An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer. Int J Radiat Oncol Biol Phys (2003) 0.78
The surgeon as a prognostic factor in the surgical treatment of rectal cancer. Surg Oncol (2007) 0.77
The current role of radiotherapy in colorectal cancer. Eur J Cancer (1995) 0.76
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol (2010) 5.65
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2001) 3.37
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2012) 3.00
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A (2009) 2.63
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer (2002) 2.51
Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell (2005) 2.47
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol (2009) 2.38
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther (2007) 2.32
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res (2003) 2.18
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15
Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 2.15
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst (2005) 2.10
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol (2012) 2.07
Vitamin D status in primary hyperparathyroidism. Eur J Intern Med (2011) 2.05
Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs. Genet Epidemiol (2008) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Clinical phenotype of families with longevity. J Am Geriatr Soc (2004) 2.03
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res (2003) 1.99
ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology (2012) 1.99
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
Maximizing association statistics over genetic models. Genet Epidemiol (2008) 1.93
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90